SUZHOU, China - eTradeWire -- Crystal Pharmatech, a global leader in solid-state and formulation science, today announced the official launch of its new OEB4/OEB5 high-potency laboratory at its headquarters in Suzhou, China. The facility has successfully passed rigorous third-party exposure control testing and is now fully operational.

The state-of-the-art laboratory features full-room negative pressure containment, dedicated gowning areas, an independent exhaust system, and five high-performance isolators compliant with ISPE standards and JG/T385:2012. It is equipped with advanced instrumentation including XRPD, TGA, DSC, and high-precision analytical balances to support safe solid-state research and crystallization under containment.

More on eTradeWire News

• Indiana Picture Cars Opens as the Premier Source for Picture Car Rentals in Indiana
• Sharon Musgrave Releases Inspirational New Single "The Best Is Yet to Come"
• The J's Semi-Annual Used Book Sale Returns Aug. 23–27, 2026
• SlipSync + Kalshi Tracking: Automated Prediction Market Support is Here
• KeywordOrbit Launches Desktop Keyword Research App With Unlimited Google Autocomplete Expansion

This new Suzhou facility complements Crystal Pharmatech's existing OEB4/OEB5 capabilities at its U.S. site in Cranbury, New Jersey, creating seamless dual-continent support for highly potent APIs (HPAPIs), including oncology and targeted small-molecule therapies.

Clients can now access integrated early-stage services such as Mol2Med™ Developability Assessment, polymorph screening, solid-state characterization, single crystal structure determination, preformulation, and small-scale crystallization process development (≤20 g) in a fully contained environment.

The expansion strengthens Crystal Pharmatech's position as a trusted global CDMO partner, helping biotech companies reduce development risks, accelerate timelines, ensure operator safety, and advance complex drug programs with confidence.

About Crystal Pharmatech

Crystal Pharmatech provides end-to-end solid-state and formulation solutions from preclinical to clinical stages, with operations in China, the United States, and Canada.